Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company specializing in precision medicines for oncology, has announced its participation in the upcoming 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Ron Bentsur, the company's Chairman and CEO, will deliver a presentation on May 20th, 2025, from 10:30 to 11:00 a.m. ET. The presentation will be accessible via webcast for interested investors and stakeholders.
Nuvectis Pharma (NASDAQ: NVCT), un'azienda biofarmaceutica in fase clinica specializzata in medicine di precisione per l'oncologia, ha annunciato la sua partecipazione al prossimo 3° Annuale H.C. Wainwright Global BioConnect Investor Conference. Ron Bentsur, Presidente e CEO dell'azienda, terrà una presentazione il 20 maggio 2025, dalle 10:30 alle 11:00 ET. La presentazione sarà disponibile in webcast per investitori e stakeholder interessati.
Nuvectis Pharma (NASDAQ: NVCT), una compañía biofarmacéutica en etapa clínica especializada en medicamentos de precisión para oncología, ha anunciado su participación en la próxima 3ra Conferencia Anual de Inversores H.C. Wainwright Global BioConnect. Ron Bentsur, presidente y CEO de la empresa, realizará una presentación el 20 de mayo de 2025, de 10:30 a 11:00 a.m. ET. La presentación estará disponible vía webcast para inversores y partes interesadas.
Nuvectis Pharma (NASDAQ: NVCT)는 정밀 의학을 전문으로 하는 임상 단계의 바이오제약 회사로, 다가오는 제3회 연례 H.C. Wainwright 글로벌 BioConnect 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 회사의 회장 겸 CEO인 Ron Bentsur가 2025년 5월 20일 동부 표준시 기준 오전 10시 30분부터 11시까지 발표를 진행할 예정입니다. 해당 발표는 관심 있는 투자자 및 이해관계자를 위해 웹캐스트로 제공됩니다.
Nuvectis Pharma (NASDAQ: NVCT), une société biopharmaceutique en phase clinique spécialisée dans les médicaments de précision pour l'oncologie, a annoncé sa participation à la prochaine 3e conférence annuelle H.C. Wainwright Global BioConnect Investor. Ron Bentsur, président et CEO de l'entreprise, fera une présentation le 20 mai 2025, de 10h30 à 11h00 ET. La présentation sera accessible en webcast pour les investisseurs et parties prenantes intéressés.
Nuvectis Pharma (NASDAQ: NVCT), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Präzisionsmedizin in der Onkologie spezialisiert hat, hat seine Teilnahme an der bevorstehenden 3. jährlichen H.C. Wainwright Global BioConnect Investorenkonferenz angekündigt. Ron Bentsur, Vorsitzender und CEO des Unternehmens, wird am 20. Mai 2025 von 10:30 bis 11:00 Uhr ET eine Präsentation halten. Die Präsentation wird für interessierte Investoren und Stakeholder per Webcast zugänglich sein.
- None.
- None.
Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference.
| Event | 3rd Annual H.C. Wainwright BioConnect Investor Conference |
| Date | May 20th, 2025 |
| Time | 10:30 – 11:00 a.m. ET |
| Link | Nuvectis Pharma Presentation Webcast Link |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900's unique mechanism of action enables the inhibition of both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
rbentsur@nuvectis.com
Media Relations Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
When is Nuvectis Pharma (NVCT) presenting at the H.C. Wainwright BioConnect Conference 2025?
Who will represent Nuvectis Pharma (NVCT) at the H.C. Wainwright Conference 2025?
What is Nuvectis Pharma's (NVCT) main business focus?
How can investors access Nuvectis Pharma's (NVCT) presentation at the H.C. Wainwright Conference?
